Navigation Links
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/14/2009

5,529) -- (29,482) Impairment loss on building (248,730) -- (248,730) -- Foreign exchange loss (10) -- (10) -- Total other Income (Expense) (248,557) (14,087) (248,247) (27,961) Income before income taxes 5,215,423 2,003,543 7,524,606 4,108,571 Provision for income taxes 1,360,246 245,577 1,840,397 529,475 Net income $3,855,177 $1,757,966 $5,684,209 $3,579,096 Net income per common share Basic $0.17 $0.08 $0.24 $0.16 Diluted $0.16 $0.08 $0.24 $0.15 Weighted average common shares outstanding Basic 23,240,899 22,152,311 23,240,899 22,152,311 Diluted 23,659,071 23,240,899 23,659,071 23,240,899 BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Six Months Ended June 30, 2009 2008 CASH FLOWS FROM OPERATING ACTIVITIES Net income $5,684,209 $3,579,096 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 332,468 319,598 Provision for doubtful accounts -- 186,085 Impairment loss on building 248,730 -- Changes in operating assets and liabilities: Accounts receivable (3,582,534) (6,163,071) Inventories (244,529) (141,382) Deposit
'/>"/>
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
2. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
3. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
4. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
5. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
9. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
10. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Egenix, Inc. is pleased to ... Chairman of the Board, to succeed Donald Fresne ; ... will continue as a member of the Board.  In recognition ... to the company over almost twenty years, the Board designated ... of Directors has established a Search Committee to find a ...
(Date:12/17/2014)... 16, 2014 “Never say, ‘I ... Universität Marburg’s Department of Physics, advises young women ... newly released SPIE Women in Optics 18-month ... shy to ask questions.” , In the annual ... mathematics) occupations ranging from university professor and laboratory ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... has received a $500,000 federal research grant, the company ... small-business innovation research grant from the National Science ... The funding complements the $100,000 phase I grant the ... ,According to Sal Braico, ConjuGons chief operating officer, the ...
... a rainbow arches from its HQ all the way to prison. ... sheds its old image of ENWRONG to PRISMA. After paying $665 ... identity of PRISMA while some of its executives walk to prison. ... a staff of 5000 in 25 different business units, a big ...
... use Wisconsin Impact Fund to distribute loans , , ... Technology Campus Web site . MADISON, Wis. - The Wisconsin ... , the developer of a commercial campus on Madison's south side, ... , ,The Federal New Markets Tax Credit Program offers ...
Cached Biology Technology:ConjuGon receives $500,000 to battle bacteria 2Why is Enron now called Prisma? 2Why is Enron now called Prisma? 3Novation Technology Campus gets $3.5 million boost 2
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... In recent years, the 1.5 kilos of bacteria that live ... crucial importance for our healthy functioning. Beyond their more obvious ... the development of the immune system and the neuronal system, ... European researchers on the gut microbiome will share their recent ...
... 13, 2014Food spoiling and poisoning caused by microbial contamination ... broad scope of antimicrobial approaches to kill or prevent ... a variety of natural and artificial preservative strategies, are ... Biotechnology , a peer-reviewed journal from Mary Ann Liebert, ...
... in climate change science have shifted over the past ... while new research challenges rose to the fore. Scientists ... and international policymakers will examine the state-of-the-science in "Research ... We Going?" on Feb. 14 at the American Association ...
Cached Biology News:Hot issues in climate change research to be debated at AAAS Annual Meeting 2